Clinical Trial Update: Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer

View source ↗

Summary

A pilot clinical study is evaluating whether fractional exhaled nitric oxide can serve as a prognostic biomarker for response to anti-PD-L1 immunotherapy in met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD-L1 immunotherapy

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Metastatic Non-small Cell Lung Cancer | Status: RECRUITING